P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
N. Jain,
G. Roboz,
M. Konopleva,
H. Liu,
G. Schiller,
E. Jabbour,
P. Desai,
D. Whitfield,
A. Haider,
O. Zernovak,
M. Frattini,
C. Brownstein,
R. Larson
Affiliations
N. Jain
1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston
G. Roboz
2 Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York
M. Konopleva
1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston
H. Liu
3 Medicine, The University of Chicago, Chicago
G. Schiller
4 Medicine, David Geffen School of Medicine at UCLA, Los Angeles
E. Jabbour
1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston
P. Desai
2 Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York
D. Whitfield
5 Cellectis, Inc., New York, United States of America
A. Haider
5 Cellectis, Inc., New York, United States of America
O. Zernovak
5 Cellectis, Inc., New York, United States of America
M. Frattini
5 Cellectis, Inc., New York, United States of America
C. Brownstein
5 Cellectis, Inc., New York, United States of America
